SCHEMBL19957320

SCHEMBL19957320

O=S(=O)(Oc1ccc2c(Cl)ccnc2c1)C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
HTR1A P08908 5/20 0.37
HTR1D P28221 4/20 0.37
HTR1B P28222 4/20 0.37
PDE4A P27815 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
SCN9A Q15858 2/20 0.35
SCN5A Q14524 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
PKM P14618 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SMYD3 Q9H7B4 1/20 0.34
KDR P35968 1/20 0.34
CLK2 P49760 1/20 0.34
IRAK1 P51617 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30509463 0.79 KDM4E (0.42) HTR1APDE4DSCN9ASCN5AKDM4E
SCHEMBL9796693 0.79 KDM4E (0.42) HTR1APDE4DSCN9ASCN5AKDM4E
SCHEMBL3894223 0.78 SRC (0.45) KDR
SCHEMBL3551410 0.77 HTR1A (0.46) HTR1AKDRCLK2IRAK1NEK4
SCHEMBL19643597 0.77 LMNA (0.43) CA1CA2HTR1AKDM4EKDR
SCHEMBL8501623 0.76 SMN1; SMN2 (0.50) PDE4APDE4CPDE4DKDM4EALDH1A1
SCHEMBL31731617 0.76 TLR8 (0.41) CA1CA2SCN9ACHRM1DRD2
SCHEMBL17310149 0.75 CA1 (0.40) CA1CA2HTR1AHTR1DHTR1B
SCHEMBL6226160 0.75 LMNA (0.42) HTR1AKDM4EALDH1A1HTTSMN1; SMN2
SCHEMBL15712195 0.74 ADORA2A (0.49) CA1CA2HTR1AHTR1DHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same Guangdong Raynovent Biotech Co., Ltd. (CN) 2020-05-19 US disclosed
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-04-25 US disclosed
EP-3293177-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ABL1, LCK, ERBB2 CA1 3462/4885CA2 1207/4885HTR1A 2710/4885
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same ABL1, LCK, ERBB2 CA1 3462/4885CA2 1207/4885HTR1A 2710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.